Patents by Inventor Kevin C. Skinner

Kevin C. Skinner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090117188
    Abstract: Methods of repairing or augmenting soft tissue in a subject are described. The methods include injecting into a subject composition comprising a biodegradable, polymerizable macromer, the macromer comprising a water soluble polymer modified with one or more biodegradable moieties; and polymerizing the macromer to provide a hydrogel, thus repairing or augmenting the soft tissue.
    Type: Application
    Filed: October 31, 2008
    Publication date: May 7, 2009
    Inventors: Julia B. Gershkovich, Peter K. Jarrett, Kevin C. Skinner, Gary D. Monheit
  • Patent number: 7022343
    Abstract: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: April 4, 2006
    Assignee: Genzyme Corporation
    Inventors: C. Michael Philbrook, James W. Burns, Kevin C. Skinner, Robert J. Miller
  • Publication number: 20020150622
    Abstract: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.
    Type: Application
    Filed: December 27, 2001
    Publication date: October 17, 2002
    Applicant: Genzyme Corporation
    Inventors: C. Michael Philbrook, James W. Burns, Kevin C. Skinner, Robert J. Miller